Overview

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
Evaluate the effect of darolutamide on the pharmacokinetics of a probe CYP3A4 substrate and Pgp substrate
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Dabigatran
Midazolam